about
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaTreatment of refractory chronic GVHD with rituximab: a GITMO study.Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant.Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia.Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia.Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasDetection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Temozolomide as salvage treatment in primary brain lymphomas.Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review.Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyFludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin.Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia
P50
Q27853209-B3E92268-CA6B-46A7-A1C7-514B11A090A7Q33375484-EBF0D35C-75DE-4438-81DD-A9F9ED25B42CQ33396632-3760454E-0540-438F-965F-87FAF03126C5Q33398869-D66D4038-C504-4E34-85B0-0C068C5ED166Q33404320-61F9B57B-D903-47B1-99FA-3BD843CD0C31Q33409149-DD52BF1E-3B50-4404-AB0F-8CA97DD0975AQ33415996-BA2620E2-0C80-4D1D-A097-1DB5E46A1271Q33430258-0D31E906-4627-46DF-91E7-5EF133DF26C9Q33433741-BDA174F9-3D06-45E8-9391-79BABD75E48AQ33437682-268E7ED2-DCD7-48B9-B340-A8DBCFA0D6A5Q33491576-E2630539-D0E1-4CE7-8A6B-5DFD9D937DBBQ33728214-6BDF5E8A-B9DC-49AB-B896-83DF626D19F0Q34461989-7318498B-0DA7-4CE7-8696-E269CD11D3AAQ35925639-F5072F6B-AD39-4C42-BA46-C0AAD9E4347CQ36204525-E24C78B6-0C23-4DAD-BB4E-55AFC95BB615Q36326340-101E2EE3-7A0D-4A52-A20E-C0833B6BC4BDQ36550468-F5797270-F866-40EB-9032-ADE5FAE68A0DQ36610071-70E1570C-FAFA-423D-B733-4707F9E6E2D5Q37848452-C7882885-1BC7-4F5B-83F4-E8D9A734FD8FQ38122437-95EEFF7A-7489-4040-AAB4-A946DD0817D5Q38815516-094557FB-BF1E-4FB8-B694-213109394EE5Q38878808-C21B06B7-9D29-475B-82AF-4B7B64EBABCEQ39307476-EC123C15-5E7C-4863-AE1F-9F9B53395D88Q40087415-8FC9736C-56CE-4109-917A-D779644B0B50Q40138440-C7F36DE5-A1A4-4D97-BF08-B81CE3E1BBE3Q40438184-89055996-9518-4ABB-A6C9-99FDF6AFB098Q40784167-9A37F7DF-90BE-48A1-966D-A76B5750C010Q42336329-51C7EC4B-84F3-483B-8336-722366BE4DE6Q42627572-BC30ADC7-2915-4944-9849-202C934631F7Q43274038-FC1DF032-9F57-450B-8E08-A2B6F9771FC8Q44166662-0CAD6B89-D2B2-4DC4-846B-8BBF82921182Q44195595-E1095F9E-7DB2-4406-A5F5-F7E5DD5A0AD8Q44752987-5242EF50-1454-4A39-A269-BFA3C927CA23Q44773928-D74137FE-F908-4268-A311-6BA67276B6D4Q44814876-C7823AD1-748A-4E14-AA1A-13382DA4ED92Q44976158-28460656-E4D3-42DD-B766-3395A43F17C5Q45018813-693E6D45-26F3-4B78-9C81-9EDBB8D488FFQ45872843-A7D5E49F-39BB-49E6-9057-8924345DDB29Q45956089-83845A9D-CA6C-4A63-8278-F27347926897Q47741058-A99E85E2-A184-4556-82BC-E52FD0366331
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco Zaja
@ast
Francesco Zaja
@en
Francesco Zaja
@es
Francesco Zaja
@nl
type
label
Francesco Zaja
@ast
Francesco Zaja
@en
Francesco Zaja
@es
Francesco Zaja
@nl
prefLabel
Francesco Zaja
@ast
Francesco Zaja
@en
Francesco Zaja
@es
Francesco Zaja
@nl
P106
P21
P31
P496
0000-0003-3995-8817